TY - JOUR
TI - The Associations of Advanced Glycation End Products and Its Soluble
Receptor with Pancreatic Cancer Risk: A Case-Control Study within the
Prospective EPIC Cohort
AU - Grote, Verena A.
AU - Nieters, Alexandra
AU - Kaaks, Rudolf and
AU - Tjonneland, Anne
AU - Roswall, Nina
AU - Overvad, Kim
AU - Nielsen, Michael
AU - R. Skjelbo
AU - Clavel-Chapelon, Francoise
AU - Boutron-Ruault, Marie
AU - Christine
AU - Racine, Antoine
AU - Teucher, Birgit
AU - Lukanova,
AU - Annekatrin
AU - Boeing, Heiner
AU - Drogan, Dagmar
AU - Trichopoulou,
AU - Antonia
AU - Trichopoulos, Dimitrios
AU - Lagiou, Pagona
AU - Palli,
AU - Domenico
AU - Sieri, Sabina
AU - Tumino, Rosario
AU - Vineis, Paolo and
AU - Mattiello, Amalia
AU - Argueelles Suarez, Marcial Vicente
AU - Duell, Eric
AU - J.
AU - Sanchez, Maria-Jose
AU - Dorronsoro, Miren
AU - Huerta Castano,
AU - Jose Maria
AU - Barricarte, Aurelio
AU - Jeurnink, Suzanne M.
AU - Peeters,
AU - Petra H. M.
AU - Sund, Malin
AU - Ye, Weimin
AU - Regner, Sara and
AU - Lindkvist, Bjorn
AU - Khaw, Kay-Tee
AU - Wareham, Nick
AU - Allen, Naomi E.
AU - and Crowe, Francesca L.
AU - Fedirko, Veronika
AU - Jenab, Mazda and
AU - Romaguera, Dora
AU - Siddiq, Afshan
AU - Bueno-de-Mesquita, H. Bas and
AU - Rohrmann, Sabine
JO - Cancer Epidemiology, Biomarkers & Prevention
PY - 2012
VL - 21
TODO - 4
SP - 619-628
PB - AMER ASSOC CANCER RESEARCH
SN - 1055-9965, 1538-7755
TODO - 10.1158/1055-9965.EPI-11-1139
TODO - null
TODO - Background: Advanced glycation end products (AGE) and their receptors
(RAGE) have been implicated in cancer development through their
proinflammatory capabilities. However, prospective data on their
association with cancer of specific sites, including pancreatic cancer,
are limited.
Methods: Prediagnostic blood levels of the AGE product
Ne-(carboxymethyl) lysine (CML) and the endogenous secreted receptor for
AGE (esRAGE) were measured using ELISA in 454 patients with exocrine
pancreatic cancer and individually matched controls within the European
Prospective Investigation into Cancer and Nutrition (EPIC). Pancreatic
cancer risk was estimated by calculating ORs with corresponding 95%
confidence intervals (CI).
Results: Elevated CML levels tended to be associated with a reduction in
pancreatic cancer risk [OR = 0.57 (95% CI, 0.32-1.01) comparing
highest with lowest quintile), whereas no association was observed for
esRAGE (OR = 0.98; 95% CI, 0.62-1.54). Adjustments for body mass index
and smoking attenuated the inverse associations of CML with pancreatic
cancer risk (OR = 0.78; 95% CI, 0.41-1.49). There was an inverse
association between esRAGE and risk of pancreatic cancer for cases that
were diagnosed within the first 2 years of follow-up [OR = 0.46 (95%
CI, 0.22-0.96) for a doubling in concentration], whereas there was no
association among those with a longer follow-up (OR = 1.11; 95% CI,
0.88-1.39; P-interaction = 0.002).
Conclusions and Impact: Our results do not provide evidence for an
association of higher CML or lower esRAGE levels with risk of pancreatic
cancer. The role of AGE/RAGE in pancreatic cancer would benefit from
further investigations. Cancer Epidemiol Biomarkers Prev; 21(4); 619-28.
(C) 2012 AACR.
ER -